INmune Bio Statistics
Total Valuation
INmune Bio has a market cap or net worth of $212.64 million. The enterprise value is $187.23 million.
| Market Cap | 212.64M |
| Enterprise Value | 187.23M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, after market close.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
INmune Bio has 18.13 million shares outstanding. The number of shares has increased by 0.30% in one year.
| Shares Outstanding | 18.13M |
| Shares Change (YoY) | +0.30% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 33.79% |
| Owned by Institutions (%) | 13.25% |
| Float | 11.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,371.86 |
| Forward PS | 1,737.24 |
| PB Ratio | 5.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,207.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.16, with a Debt / Equity ratio of 0.28.
| Current Ratio | 2.16 |
| Quick Ratio | n/a |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -64.10% and return on invested capital (ROIC) is -62.81%.
| Return on Equity (ROE) | -64.10% |
| Return on Assets (ROA) | -45.60% |
| Return on Capital (ROIC) | -62.81% |
| Revenue Per Employee | $14,091 |
| Profits Per Employee | -$2.73M |
| Employee Count | 11 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +53.76% in the last 52 weeks. The beta is 1.95, so INmune Bio's price volatility has been higher than the market average.
| Beta (1Y) | 1.95 |
| 52-Week Price Change | +53.76% |
| 50-Day Moving Average | 11.44 |
| 200-Day Moving Average | 9.62 |
| Relative Strength Index (RSI) | 52.64 |
| Average Volume (30 Days) | 102,679 |
Short Selling Information
The latest short interest is 1.50 million, so 8.28% of the outstanding shares have been sold short.
| Short Interest | 1.50M |
| Short Previous Month | 1.53M |
| Short % of Shares Out | 8.28% |
| Short % of Float | 12.81% |
| Short Ratio (days to cover) | 14.76 |
Income Statement
In the last 12 months, INmune Bio had revenue of $155,000 and -$30.01 million in losses. Loss per share was -$1.67.
| Revenue | 155,000 |
| Gross Profit | 155,000 |
| Operating Income | -30.01M |
| Pretax Income | -30.01M |
| Net Income | -30.01M |
| EBITDA | -30.01M |
| EBIT | -30.01M |
| Loss Per Share | -$1.67 |
Balance Sheet
The company has $35.85 million in cash and $10.44 million in debt, giving a net cash position of $25.41 million or $1.40 per share.
| Cash & Cash Equivalents | 35.85M |
| Total Debt | 10.44M |
| Net Cash | 25.41M |
| Net Cash Per Share | $1.40 |
| Equity / Book Value | 37.34M |
| Book Value Per Share | 2.06 |
| Working Capital | 21.48M |
Cash Flow
| Operating Cash Flow | -11.98M |
| Capital Expenditures | n/a |
| Free Cash Flow | -11.98M |
| FCF Per Share | -$0.67 |
Margins
Gross margin is 100.00%, with operating and profit margins of -19,360.00% and -19,360.00%.
| Gross Margin | 100.00% |
| Operating Margin | -19,360.00% |
| Pretax Margin | -19,360.00% |
| Profit Margin | -19,360.00% |
| EBITDA Margin | -19,360.00% |
| EBIT Margin | -19,360.00% |
| FCF Margin | -7,729.03% |
Dividends & Yields
INmune Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.30% |
| Shareholder Yield | -0.30% |
| Earnings Yield | -14.11% |
| FCF Yield | -5.63% |
Analyst Forecast
The average price target for INmune Bio is $16.00, which is 39.68% higher than the current price. The consensus rating is "Buy".
| Price Target | $16.00 |
| Price Target Difference | 39.68% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 301.19% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
INmune Bio has an Altman Z-Score of 2.51 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.51 |
| Piotroski F-Score | 2 |